Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis

Silvia Mihaela Ilie,1 Xenia Elena Bacinschi,1,2 Inga Botnariuc,2 Rodica Maricela Anghel1,2 1University of Medicine and Pharmacy “Carol Davila,” Bucharest, Romania; 2Department of Oncology-Radiotherapy, Institute of Oncology “Prof Dr Alexandru Trestioreanu,” Bu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ilie SM, Bacinschi XE, Botnariuc I, Anghel RM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	prognosis immunohistochemical biomarkers triple-negative breast cancer prognostic score Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/599720cc5ec545719c2be16397bc89bd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:599720cc5ec545719c2be16397bc89bd
record_format	dspace
spelling	oai:doaj.org-article:599720cc5ec545719c2be16397bc89bd2021-12-02T05:17:27ZPotential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis1179-1314https://doaj.org/article/599720cc5ec545719c2be16397bc89bd2018-11-01T00:00:00Zhttps://www.dovepress.com/potential-clinically-useful-prognostic-biomarkers-in-triple-negative-b-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Silvia Mihaela Ilie,1 Xenia Elena Bacinschi,1,2 Inga Botnariuc,2 Rodica Maricela Anghel1,2 1University of Medicine and Pharmacy “Carol Davila,” Bucharest, Romania; 2Department of Oncology-Radiotherapy, Institute of Oncology “Prof Dr Alexandru Trestioreanu,” Bucharest, Romania Background: Triple-negative breast cancer (TNBC) has a poor prognosis, even in its early stages. In the absence of postoperative targeted treatments, intensive adjuvant chemotherapy regimens are proposed. For those favorable histologies, such as apocrine and adenoid cystic carcinoma, which frequently belong to TNBC, aggressive treatments are unnecessary.Patients and methods: We retrospectively analyzed 631 cases of breast cancer, primary operated curatively, and followed up at our institution for at least 36 months to identify the biomarkers assessable by immunohistochemistry, to be proposed as prognostic score for tailoring adjuvant treatment to TNBC patients.Results: The triple-negative phenotype was found in 85 patients (13.5%). Over a mean follow-up of 55.7 months, relapses occurred in 106 patients (16.8%), of which 18 (2.8%) were TNBC. Recurrence was directly correlated with Ki67 and cytokeratin 5/6 (CK5/6) immunoreactivity in all breast cancer patients (P=0.005), but only marginally with CK5/6 and epithelial cadherin (E-cad) expression in TNBC patients (P=0.07). Mean event-free survival (EFS) in TNBC patients was 85.52 months compared with 100.4 months in non-TNBC patients (P=0.228). The EFS of CK5/6-negative triple-negative patients was 68.84 months compared with 98.84 months in those who were CK5/6 positive (HR =5.08; P=0.038). EFS differed among patients identified as double-positive for E-cad and CK5/6 (83.87 months), those expressing E-cad or CK5/6 (64.23 months), and those negative for both biomarkers (39.64 months).Conclusion: These preliminary results suggest that CK5/6 and E-cad are possible core biomarkers for a cost-effective prognostic evaluation of primary operable TNBC patients. Keywords: prognosis, immunohistochemical biomarkers, triple-negative breast cancer, CK5/6, E-cadherinIlie SMBacinschi XEBotnariuc IAnghel RMDove Medical Pressarticleprognosisimmunohistochemical biomarkerstriple-negative breast cancerprognostic scoreNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 10, Pp 177-194 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	prognosis immunohistochemical biomarkers triple-negative breast cancer prognostic score Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	prognosis immunohistochemical biomarkers triple-negative breast cancer prognostic score Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Ilie SM Bacinschi XE Botnariuc I Anghel RM Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis
description	Silvia Mihaela Ilie,1 Xenia Elena Bacinschi,1,2 Inga Botnariuc,2 Rodica Maricela Anghel1,2 1University of Medicine and Pharmacy “Carol Davila,” Bucharest, Romania; 2Department of Oncology-Radiotherapy, Institute of Oncology “Prof Dr Alexandru Trestioreanu,” Bucharest, Romania Background: Triple-negative breast cancer (TNBC) has a poor prognosis, even in its early stages. In the absence of postoperative targeted treatments, intensive adjuvant chemotherapy regimens are proposed. For those favorable histologies, such as apocrine and adenoid cystic carcinoma, which frequently belong to TNBC, aggressive treatments are unnecessary.Patients and methods: We retrospectively analyzed 631 cases of breast cancer, primary operated curatively, and followed up at our institution for at least 36 months to identify the biomarkers assessable by immunohistochemistry, to be proposed as prognostic score for tailoring adjuvant treatment to TNBC patients.Results: The triple-negative phenotype was found in 85 patients (13.5%). Over a mean follow-up of 55.7 months, relapses occurred in 106 patients (16.8%), of which 18 (2.8%) were TNBC. Recurrence was directly correlated with Ki67 and cytokeratin 5/6 (CK5/6) immunoreactivity in all breast cancer patients (P=0.005), but only marginally with CK5/6 and epithelial cadherin (E-cad) expression in TNBC patients (P=0.07). Mean event-free survival (EFS) in TNBC patients was 85.52 months compared with 100.4 months in non-TNBC patients (P=0.228). The EFS of CK5/6-negative triple-negative patients was 68.84 months compared with 98.84 months in those who were CK5/6 positive (HR =5.08; P=0.038). EFS differed among patients identified as double-positive for E-cad and CK5/6 (83.87 months), those expressing E-cad or CK5/6 (64.23 months), and those negative for both biomarkers (39.64 months).Conclusion: These preliminary results suggest that CK5/6 and E-cad are possible core biomarkers for a cost-effective prognostic evaluation of primary operable TNBC patients. Keywords: prognosis, immunohistochemical biomarkers, triple-negative breast cancer, CK5/6, E-cadherin
format	article
author	Ilie SM Bacinschi XE Botnariuc I Anghel RM
author_facet	Ilie SM Bacinschi XE Botnariuc I Anghel RM
author_sort	Ilie SM
title	Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis
title_short	Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis
title_full	Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis
title_fullStr	Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis
title_full_unstemmed	Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis
title_sort	potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/599720cc5ec545719c2be16397bc89bd
work_keys_str_mv	AT iliesm potentialclinicallyusefulprognosticbiomarkersintriplenegativebreastcancerpreliminaryresultsofaretrospectiveanalysis AT bacinschixe potentialclinicallyusefulprognosticbiomarkersintriplenegativebreastcancerpreliminaryresultsofaretrospectiveanalysis AT botnariuci potentialclinicallyusefulprognosticbiomarkersintriplenegativebreastcancerpreliminaryresultsofaretrospectiveanalysis AT anghelrm potentialclinicallyusefulprognosticbiomarkersintriplenegativebreastcancerpreliminaryresultsofaretrospectiveanalysis
_version_	1718400469726920704

Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis

Ejemplares similares